Abstract
Normal hematopoietic cells express telomerase activity, however the presence of telomerase does not necessarily imply stable and thus unchanging telomere length. Gradual telomere loss with aging and rapid cycling of hematopoietic stem cells might contribute to immunosenescence, exhausted hematopoiesis, and increased likelihood of malignant transformation. In leukemias and lymphomas, telomere length may reflect the cellular proliferative history, prior to immortalization. The level of telomerase activity is generally influenced by the fraction of cells in the proliferative pool. Shortened telomeres and high telomerase activity almost always correlates with disease severity in hematologic neoplasias such as relapsed leukemia and high-grade lymphomas, indicating that measurement of telomere length and telomerase activity might be useful to monitor disease condition. Since the mode of action of telomerase inhibitors may require telomeric shortening before induction of apoptosis, anti-telomerase therapy might be helpful for adjuvant therapy following conventional chemotherapy, in vitro purging of neoplastic cells in stem cell transplantation, and treating minimal residual disease. Some promising areas of tissue engineering include rejuvenation of hematopoietic stem cells for improving stem cell transplants or enhancing general immunity for older patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiyama M, Hoshi Y, Sakurai H, Yamada H, Yamada O, Mizoguchi H . 1998 Bone Marrow Transplant 21: 167–171
Akiyama M, Asai O, Kuraishi Y, Urashima M, Hoshi Y, Sakamaki H, Yabe H, Furukawa T, Yamada O, Mizoguchi H, Yamada H . 2000 Bone Marrow Transplant 25: 441–447
Allsopp RC, Cheshier S, Weissman IL . 2001 J. Exp. Med. 193: 917–924
Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S . 2001 Blood 97: 2903–2907
Baur JA, Zou Y, Shay JW, Wright WE . 2001 Science 292: 2075–2077
Bearss DJ, Bearss DJ, Subler MA, Hundley JE, Troyer DA, Salinas RA, Windle JJ . 2000 Oncogene 19: 1114–1122
Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J . 1998 Cancer Res. 58: 4918–4922
Bergemann J, Kuhlcke K, Fehse B, Ratz I, Ostertg W, Lother H . 1995 Nucleic Acids Res. 23: 4451–4456
Boultwood J, Fidler C, Kusec R, Rack K, Elliott PJ, Atoyebi O, Chapman R, Oscier DG, Wainscoat JS . 1997 Am. J. Hematol. 56: 266–271
Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ, Wainscoat JS . 2000 Blood 96: 358–361
Broccoli D, Young JW, de Lange T . 1995 Proc. Natl. Acad. Sci. USA 92: 9082–9086
Brousset P, al Saati T, Chaouche N, Zenou RC, Schlaifer D, Chittal S, Delsol G . 1997 Blood 89: 26–31
Brousset P, Chaouche N, Al Saati T, Zenou RC, Delsol G . 1998 Leuk. Lymphoma 30: 189–192
Brummendorf TH, Holyake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM . 2000 Blood 95: 1883–1890
Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM . 2001 Blood 97: 895–900
Busson Le Coniat M, Brizard F, Smadja NV, Maarek O, Der Sarkissian H, Berger R . 2000 Leukemia 14: 1630–1633
Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley CB, Lansdorp PM . 1996 Stem Cells 14: 239–248
Counter CM, Gupta J, Harley CB, Lebe B, Bacchetti S . 1995 Blood 85: 2315–2320
Cuthbert G, McCullough S, Finney R, Breese G, Bown N . 1999 Genes Chromosomes Cancer 24: 295–298
Daibata M, Taguchi T, Nemoto Y, Taguchi H, Miyoshi I . 1999 Blood 94: 1545–1549
Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM . 2000 Cancer 89: 445–452
Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MAS . 1997 Blood 90: 182–193
Engelhardt M, Mackebzie K, Drullinsky P, Silver RT, Moore MAS . 2000 Cancer Res. 60: 610–617
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J . 1997 Blood 89: 2079–2088
Guiducci C, Cerone MA, Bacchetti S . 2001 Oncogene 20: 714–725
Harada K, Kurisu K, Arita K, Sadatomo T, Tahara H, Tahara E, Ide T, Uozumi T . 1999 Cancer 86: 1050–1055
Hatakeyama S, Osawa M, Omine M, Ishikawa F . 1999 Oncogene 18: 2085–2090
Hiyama K, Hirai Y, Koizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S, Yamakodo M . 1995 J. Immunol. 155: 3711–3715
Holt SE, Wright WE, Shay JW . 1996 Mol. Cell. Biol. 16: 2932–2939
Igarashi H, Sakaguchi N . 1996 Biochem. Biophys. Res. Commun. 219: 649–655
Igarashi H, Sakaguchi N . 1997 Blood 89: 1299–1307
Iwama H, Ohyashiki K, Ohyashiki JH, Hayashi S, Kawakubo K, Shay JW, Toyama K . 1997 Cancer 79: 1552–1560
Iwama H, Ohyashiki K, Ohyashiki JH, Hayashi S, Yahata N, Ando K, Toyama K, Hoshika A, Takasaki M, Mori M, Shay JW . 1998 Human Genet. 102: 397–402
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW . 1994 Science 266: 2011–2015
Lee J, Kook H, Chung I, Kim H, Park M, Kim C, Nah J, Hwang T . 1999 Bone Marrow Transplant 24: 411–415
Li B, Yang J, Andrews C, Chen YX, Toofanfard P, Huang RW, Horvath E, Chopra H, Raza A, Preisler HD . 2000 Leuk. Lymphoma 36: 579–587
Nakajima A, Tauchi T, Ohyashiki K . 2001 Leukemia 15: 989–990
Nilsson P, Mehle C, Remes K, Roos G . 1994 Oncogene 9: 3043–3048
Norrback K-F, Dahlenborg K, Carlsson R, Roos G . 1996 Blood 88: 222–229
Norrback KF, Roos G . 1997 Eur. J. Cancer 33: 774–780
Norrback KF, Enblad G, Erlanson M, Sundstrom C, Roos G . 1998 Blood 92: 567–573
Notaro R, Cimmino A, Tabarini D, Rotoli B, Luzzatto L . 1997 Proc. Natl. Acad. Sci. USA 94: 13782–13785
Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, Toyama K . 1994 Cancer Res. 54: 3557–3560
Ohyashiki JH, Ohyashiki K, Toyama K, Shay JW . 1996 Trends. Genet. 12: 395–396
Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW . 1997a Clin. Cancer Res. 3: 619–625
Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K . 1997b Leukemia 11: 190–194
Ohyashiki JH, Iwama H, Yahata N, Ando K, Hayashi S, Shay JW, Ohyashiki K . 1999 Clin. Cancer Res. 5: 1155–1160
Ohyashiki JH, Hayashi S, Yahata N, Iwama H, Ando K, Tauchi T, Ohyashiki K . 2001 Int. J. Oncol. 18: 593–598
Pan C, Xue BH, Ellis TM, Peace DJ, Diaz MO . 1997 Exp. Cell Res. 231: 346–353
Remes K, Norrback KF, Rosenquist R, Mehle C, Lindh J, Roos G . 2000 Br. J. Cancer 82: 601–607
Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM . 1998 Nat. Biotechnol. 16: 743–747
Rufer N, Brummendorf TH, Chpuis B, Helg C, Lansdorp PM, Poosnek E . 2001 Blood 97: 575–577
Sakabe H, Yahata N, Kimura T, Zeng ZZ, Minamiguchi H, Kaneko H, Mori KJ, Ohyashiki K, Ohyashiki JH, Toyama K, Abe T, Sonoda Y . 1998 Leukemia 12: 728–734
Shay JW, Werbin H, Wright WE . 1996 Leukemia 10: 1255–1261
Shay JW . 1998 Lancet 351: 153–154
Shay JW, Wright WE . 2000 Nat. Biotechnol. 18: 22–23
Steinert S, Shay JW, Wright WE . 2000 Biochem. Biophys. Res. Commun. 273: 1095–1098
Takeuchi K, Tashiro S, Ohtaki M, Kamada N . 1994 Jpn. J. Cancer Res. 85: 127–130
Tatematsu K, Nakayama J, Danbara M, Shionoya S, Sato H, Omine M, Ishikawa F . 1996 Oncogene 13: 2265–2274
Thomas M, Yang L, Hornsby PJ . 2000 Nat. Biotechnol. 18: 39–42
Trentin L, Ballon G, Ometto L, Perin A, Basso U, Chieco-Bianchi L, Semenzato G, De Rossi A . 1999 Br. J. Haematol. 106: 662–668
Vaziri H, Dragowska W, Allosopp RC, Thomas TE, Harley CB, Lansdrop PM . 1994 Proc. Natl. Acad. Sci. USA 91: 9857–9860
Vonderheide RH, Hahn WC, Schulze JL, Nadler LM . 1999 Immunity 10: 673–679
Weng N-P, Levine BL, June CH, Hodes RJ . 1996 J. Exp. Med. 183: 2471–2479
Wright WE, Shay JW, Pietyszek MA . 1995 Nucleic Acid Res. 23: 3794–3795
Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, Testa NG . 1998 Lancet 351: 178–181
Xu D, Gruber A, Peterson C, Pisa P . 1998 Br. J. Haematol. 102: 1367–1375
Xu D, Gruber A, Bjorkholm M, Peterson C, Pisa P . 1999 Br. J. Cancer 80: 1156–1161
Yamada O, Oshimi K, Motoji T, Mizoguchi H . 1995 J. Clin. Invest. 95: 1117–1123
Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR . 1999 Cancer Res. 59: 4175–4179
Yui J, Chiu CP, Lansdorp PM . 1998 Blood 91: 3255–3262
Zhang W, Pietyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB, Wright WE, Shay JW . 1996 Clin. Cancer Res. 2: 799–803
Acknowledgements
The authors wish to thank Profs Jerry W Shay (University of Texas Southwestern Medical Center) and Peter L Greenberg (Stanford University) for critical reading of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohyashiki, J., Sashida, G., Tauchi, T. et al. Telomeres and telomerase in hematologic neoplasia. Oncogene 21, 680–687 (2002). https://doi.org/10.1038/sj.onc.1205075
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205075
Keywords
This article is cited by
-
Effects of PCB126 and PCB153 on telomerase activity and telomere length in undifferentiated and differentiated HL-60 cells
Environmental Science and Pollution Research (2016)
-
Expression pattern of hTERT telomerase subunit gene in different stages of chronic myeloid leukemia
Molecular Biology Reports (2014)
-
Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia
Journal of Hematology & Oncology (2013)
-
Cancer stem cells and cancer therapy
Tumor Biology (2011)
-
Telomerase downregulation in cancer brain stem cell
Molecular and Cellular Biochemistry (2009)